Joel Neal, MD, PhD

Medical oncologist, Thoracic specialist

Assistant Professor of Medicine (Oncology) at the Stanford University Medical Center

Thoracic Cancer Program

  • 875 Blake Wilbur Drive
  • Palo Alto, CA 94304
  • Phone: 650-498-6000
Learn More About the Clinic Getting Here Make An Appointment

Professional Education

Board Certification: Medical Oncology, American Board of Internal Medicine (2010)

Medical Education: Feinberg School of Medicine - Northwestern University (05/2004) IL

Fellowship: Dana-Farber Cancer Institute (08/2010) MA

Residency: Beth Israel Deaconess Medical Center (06/2007) MA

Board Certification: Internal Medicine, American Board of Internal Medicine (2007)

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements
Riess, J. W., Padda, S. K., Bangs, C. D., Das, M., Neal, J. W., & Wakelee, H. A. (2013). A Case Series of Lengthy Progression-Free Survival With Pemetrexed-Containing Therapy in Metastatic Non-Small-Cell Lung Cancer Patients Harboring ROS1 Gene Rearrangements. CLINICAL LUNG CANCER, 14(5), 592-595.

A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib
Riess, J. W., Nagpal, S., Neal, J. W., & Wake, H. A. (2013). A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 11(4), 389-394.

A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab.
Riess, J. W., Nagpal, S., Das, M., Neal, J. W., Kim, J. W., & Wakelee, H. A. (2013). A case series of NSCLC patients with different molecular characteristics and choroidal metastases: improvement in vision with treatment including pemetrexed and bevacizumab. Journal of thoracic oncology , 8(2), e17-8.

Aflibercept in lung cancer
Neal, J. W., & Wakelee, H. A. (2013). Aflibercept in lung cancer. EXPERT OPINION ON BIOLOGICAL THERAPY, 13(1), 115-120.

Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.
Riess, J. W., & Neal, J. W. (2012). Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer. Journal of thoracic oncology , 7(16), S385-6.

A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer
Goldberg, S. B., Supko, J. G., Neal, J. W., Muzikansky, A., Digumarthy, S., & Sequist, L. V. (2012). A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small-Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 7(10), 1602-1608.

Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
Neal, J. W., & Sequist, L. V. (2012). Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer. JOURNAL OF CLINICAL ONCOLOGY, 30(18), 2280-2282.

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., & Reck, M. (2012). Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non-Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study. JOURNAL OF CLINICAL ONCOLOGY, 30(17), 2046-2054.

First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.
Nguyen, K.-S. H., & Neal, J. W. (2012). First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors. Biologics : targets & therapy, 6, 337-345.

Current Management of Small Cell Lung Cancer
Neal, J. W., Gubens, M. A., & Wakelee, H. A. (2011). Current Management of Small Cell Lung Cancer. CLINICS IN CHEST MEDICINE, 32(4), 853-?.

Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer
Riess, J. W., & Neal, J. W. (2011). Targeting FGFR, Ephrins, Mer, MET, and PDGFR-alpha in Non-small Cell Lung Cancer. JOURNAL OF THORACIC ONCOLOGY, 6(11), S1797-S1798.

One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer
Neal, J. W., & Shaw, A. T. (2011). One Allele's Loss Is Another's Gain: Alterations of NKX2-8 in Non-Small Cell Lung Cancer. CLINICAL CANCER RESEARCH, 17(4), 638-639.

The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer
Neal, J. W. (2010). The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. FUTURE ONCOLOGY, 6(12), 1827-1832.

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal, J. W., Heist, R. S., Fidias, P., Temel, J. S., Huberman, M., & Sequist, L. V. (2010). Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy. Journal of thoracic oncology , 5(11), 1855-1858.

AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer
Neal, J., & Wakelee, H. (2010). AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer. CURRENT OPINION IN MOLECULAR THERAPEUTICS, 12(4), 487-495.

Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh
Neal, J. W., & Sequist, L. V. (2010). Exciting New Targets in Lung Cancer Therapy: ALK, IGF-1R, HDAC, and Hh. CURRENT TREATMENT OPTIONS IN ONCOLOGY, 11(1-2), 36-44.

Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
Neal, J. W., & Sequist, L. V. (2010). Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations. Nature reviews. Clinical oncology, 7(2), 71-72.

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Neal, J. W., & Sequist, L. V. (2010). First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations. Clinical advances in hematology & oncology : H&O, 8(2), 119-126.

Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells
Barry, S. M., Zisoulis, D. G., Neal, J. W., Clipstone, N. A., & Kansas, G. S. (2003). Induction of FucT-VII by the Ras/MAP kinase cascade in Jurkat T cells. BLOOD, 102(5), 1771-1778.

A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts
Neal, J. W., & Clipstone, N. A. (2003). A constitutively active NFATc1 mutant induces a transformed phenotype in 3T3-L1 fibroblasts. JOURNAL OF BIOLOGICAL CHEMISTRY, 278(19), 17246-17254.

Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells
Neal, J. W., & Clipstone, N. A. (2002). Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells. JOURNAL OF BIOLOGICAL CHEMISTRY, 277(51), 49776-49781.

Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc
Neal, J. W., & Clipstone, N. A. (2001). Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. JOURNAL OF BIOLOGICAL CHEMISTRY, 276(5), 3666-3673.

REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE-ACTIVATED ATP-DEPENDENT PHOSPHORYLATION OF HPR IN LACTOBACILLUS-BREVIS
Ye, J. J., Neal, J. W., Cui, X. W., Reizer, J., & Saier, M. H. (1994). REGULATION OF THE GLUCOSE-H+ SYMPORTER BY METABOLITE-ACTIVATED ATP-DEPENDENT PHOSPHORYLATION OF HPR IN LACTOBACILLUS-BREVIS. JOURNAL OF BACTERIOLOGY, 176(12), 3484-3492.